Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.59 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.59 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.59 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 4/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4709350 | 0.99 | HDAC3 (0.59) | MAOBHDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL3493914 | 0.90 | RAB9A (0.58) | MAOBHDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL27564853 | 0.88 | MEN1 (0.60) | MAOBHDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL433676 | 0.87 | MAOB (0.65) | MAOBHDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL70341 | 0.86 | ALDH1A1 (0.63) | MAOBHDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL3167665 | 0.86 | MAOB (0.62) | MAOBRAB9ASMN1; SMN2NPC1MAPK1 | |
| SCHEMBL10547122 | 0.85 | RAB9A (0.65) | MAOBRAB9ASMN1; SMN2NPC1MAPK1 | |
| SCHEMBL1819500 | 0.85 | PTPN1 (0.68) | MAOBNR4A1NR4A2NR4A3NR1H4 | |
| SCHEMBL1747129 | 0.84 | NR1H4 (0.54) | MAOBHDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL11830013 | 0.84 | NPC1 (0.62) | RAB9ASMN1; SMN2NPC1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645772-B2 | 4-(4-benzyloxy-3-chlorophenyl)-4-oxobutanoic acid; Methyl 4-(4-benzyloxy-2-methoxyphenyl)-4-oxobutanoate or derivatives for treatment of insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-01-12 | — | — | US | claimed |
| US-20060035970-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2006-02-16 | — | — | US | claimed |
| EP-1556085-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2005-07-27 | — | — | EP | claimed |
| WO-2004041165-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2004-05-21 | — | — | WO | claimed |
| WO-2020080960-A1 | COMPOUNDS FOR TREATING DIABETES AND/OR RELATED CONDITIONS | AUCKLAND UNISERVICES LIMITED (NZ) | 2020-04-23 | — | — | WO | disclosed |
| EP-1310494-B1 | PPAR (delta) ACTIVATORS | NIPPON CHEMIPHAR CO (JP) | 2012-01-25 | — | — | EP | disclosed |
| EP-1424330-B1 | ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR DELTA | NIPPON CHEMIPHAR CO (JP) | 2011-09-28 | — | — | EP | disclosed |
| EP-2213638-A1 | Method for the asymmetric hydrogenation of olefins utilising photoisomerisation | DSM IP Assets B.V. (NL) | 2010-08-04 | — | — | EP | disclosed |
| US-7666863-B2 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED (US) | 2010-02-23 | — | — | US | disclosed |
| US-7652045-B2 | e.g. [[7-Allyl-3-[2-[2-(2,4-dichlorophenyl)-5-isopropyl-4-oxazolyl]ethyl]-1,2-benzisoxazol-6-yl]oxy]acetic acid; with vehicles (lactose, D-mannitol, glucose), disintegrators (starch or carboxymethylcellulose calcium ), binders (hydroxypropylcellulose) and lubricants (magnesium stearate or talc) | NIPPON CHEMIPHAR, CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| WO-2010006954-A1 | NOVEL N-SUBSTITUTED BETA-AMINO ACID ESTERS | DSM IP ASSETS B.V. (NL) | 2010-01-21 | — | — | WO | disclosed |
| US-7648999-B2 | Activator for peroxisome proliferator-activated receptor δ | NIPPON CHEMIPHAR CO., LTD. (JP) | 2010-01-19 | — | — | US | disclosed |
| WO-2004041201-A2 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004041165-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040097739-A1 | Ppar delta activators | NIPPON CHEMIPHAR CO., LTD. (JP) | 2004-05-20 | — | — | US | disclosed |
| US-20040038993-A1 | Pyrazolo[1,5a]pyrimidine compounds as antiviral agents | NEOGENESIS PHARMACEUTICALS, INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2003101993-A1 | PYRAZOLO` 1,5A! PYRIMIDINE COMPOUNDS AS ANTIVIRAL AGENTS | NEOGENESIS PHARMACEUTICALS, INC. (US) | 2003-12-11 | — | — | WO | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
| EP-1310494-A1 | PPAR (delta) ACTIVATORS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2003-05-14 | — | — | EP | disclosed |
| WO-1998025608-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A 4-ARYLCOUMARIN FOR THE TREATMENT OF VIRAL INFECTIONS | BIO'S S.R.L. (IT) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038993-A1 | Pyrazolo[1,5a]pyrimidine compounds as antiviral agents | RNGTT, PNP, ZC3HAV1 | MAOB 1460/4885HDAC3 1497/4885HDAC1 1713/4885 |
| US-20040097739-A1 | Ppar delta activators | PPARD, PPARG, PPARA | MAOB 4119/4885HDAC3 132/4885HDAC1 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.